Hengrui Medicine continues share buyback program

Jiangsu Hengrui Medicine (SSE: 600276) announced the ongoing progress of its share repurchase program. As of March 11, 2025, the company had cumulatively repurchased 5,898,044 shares, representing 0.09% of the company's total share capital. The highest price paid per share was 57.01 yuan, and the lowest was 39.00 yuan. The total expenditure for the repurchase reached 250,613,211.80 yuan (excluding transaction costs). The buyback is intended for the employee stock ownership plan. The company stated it would continue to implement the repurchase program in compliance with relevant regulations, making repurchase decisions based on market conditions while fulfilling information disclosure obligations. The initial announcement of this plan was made on May 16, 2024 and is valid for 12 months following board approval. The initial total value expected for the scheme was between 600 million yuan and 1.2 billion yuan.